- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Affinity Label.
Displaying page 1 of 1.
EudraCT Number: 2020-004176-18 | Sponsor Protocol Number: CHK01-02 | Start Date*: 2021-06-21 |
Sponsor Name:Chinook Therapeutics U.S., Inc. | ||
Full Title: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) | ||
Medical condition: Proteinuric glomerular diseases, including: Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g) Focal segmental glomerulosclerosis (FSGS) Alport Syndrome Diabetes kidney disease (DKD) (... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000148-76 | Sponsor Protocol Number: 3.0 | Start Date*: 2021-08-04 |
Sponsor Name:Stockholm Health Care Services | ||
Full Title: Effects of Montelukast on neuroinflammation in Parkinson's Disease. An open-label single-center trial. | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017798-39 | Sponsor Protocol Number: PROVAX study | Start Date*: 2010-07-08 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) | |||||||||||||
Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000253-36 | Sponsor Protocol Number: CD-IA-MEDI-551-1155 | Start Date*: 2014-12-08 | |||||||||||
Sponsor Name:MedImmune LLC | |||||||||||||
Full Title: A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disord... | |||||||||||||
Medical condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) EE (Prematurely Ended) BG (Completed) PL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) GR (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003528-33 | Sponsor Protocol Number: VIB0551.P2.S2.NMO | Start Date*: 2022-04-13 | |||||||||||
Sponsor Name:Horizon Therapeutics Ireland DAC | |||||||||||||
Full Title: An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder | |||||||||||||
Medical condition: Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO]) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) SE (Trial now transitioned) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018780-42 | Sponsor Protocol Number: OMB113676 | Start Date*: 2010-10-28 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy | ||
Medical condition: Indolent B-Cell Non-Hodgkin's Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) BE (Completed) FR (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000893-69 | Sponsor Protocol Number: BN42082 | Start Date*: 2020-10-28 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | ||||||||||||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis (MS) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) FR (Ongoing) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002008-11 | Sponsor Protocol Number: IMC-M113V-103 | Start Date*: 2021-11-24 | |||||||||||
Sponsor Name:Immunocore Limited | |||||||||||||
Full Title: An open-label dose-escalation study evaluating the safety, pharmacokinetics and antiviral activity of IMC-M113V in HLA-A*02:01-positive subjects with chronic HIV infection who are virologically sup... | |||||||||||||
Medical condition: Chronic HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000826-22 | Sponsor Protocol Number: CBLZ945C12201 | Start Date*: 2019-09-17 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m... | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001498-15 | Sponsor Protocol Number: BP29360 | Start Date*: 2014-08-29 | |||||||||||
Sponsor Name:F. Hoffmann- La Roche Ltd. | |||||||||||||
Full Title: OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HIST... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) ES (Completed) NL (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000894-26 | Sponsor Protocol Number: BN42083 | Start Date*: 2020-10-12 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL... | |||||||||||||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis (MS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Ongoing) DE (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) IT (Ongoing) BG (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001790-23 | Sponsor Protocol Number: GCT1047-01 | Start Date*: 2021-09-27 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors | |||||||||||||
Medical condition: Malignant Solid Tumors, per protocol GCT1047-01 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003400-24 | Sponsor Protocol Number: I3Y-MC-JPBZ | Start Date*: 2016-01-29 |
Sponsor Name:Lilly S.A. | ||
Full Title: monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physic... | ||
Medical condition: Hormone receptor positive, HER2-positive advanced breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) GR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002915-23 | Sponsor Protocol Number: ARGX-113-1904 | Start Date*: 2021-01-25 | ||||||||||||||||
Sponsor Name:argenx BV | ||||||||||||||||||
Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS) | ||||||||||||||||||
Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) BG (Completed) GR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.